Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=47234#.VFwtFGfHRK1
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=47234#.VFwtFGfHRK1
Author(s)
Cape Fear Valley Hospital NC, Fayetteville, USA.
St. Luks/Roosevelet Hospital, New York, USA.
South Texas Regional Medical Center, San Antonio, USA.
New York Hospital Queens, New York, USA.
Columbia Medical University, New York, USA.
New York Hospital Queens, New York, USA.
New York Hospital Queens, New York, USA.
New York Hospital Queens, New York, USA.
St. Luks/Roosevelet Hospital, New York, USA.
South Texas Regional Medical Center, San Antonio, USA.
New York Hospital Queens, New York, USA.
Columbia Medical University, New York, USA.
New York Hospital Queens, New York, USA.
New York Hospital Queens, New York, USA.
New York Hospital Queens, New York, USA.
One of the major
elements contributing to anemia in Chronic Kidney Disease (CKD) patients is
iron deficiency. Iron supplementation in oral form is often not tolerated and
ineffectively absorbed. Intravenous (IV) infusion is time consuming and is
inconvenient in Peritoneal Dialysis (PD) patients self-treating at home. A new
preparation of iron, ferumoxytol, is a carbohydrate-coated, paramagnetic iron
oxide nanoparticle, which can be administered as a bolus intravenous injection,
allowing the PD patient to more easily comply with current IV iron dosing
regimens. Few studies have been done to evaluate the efficacy of ferumoxytol in
PD population. We retrospectively reviewed the medical records of peritoneal
dialysis patients who received at least one dose of ferumoxytol between January
2010 and August 2010 and observed that 17 patients showed an improvement in
hemoglobin (Hb) to 1 gm/dl within a month of treatment along with a decrease in
epoetin dosage in subsequent weeks.
KEYWORDS
Cite this paper
Husain, S. , Judeh, H. , Alroumoh, M. , Yousaf, F. ,
Mohan, P. , Husain, A. , Charytan, C. and Spinowitz, B. (2014) The
Efficacy of Ferumoxytol in Peritoneal Dialysis Patients: A Short
Scientific Report. Open Journal of Nephrology, 4, 100-102. doi: 10.4236/ojneph.2014.42014.
| [1] |
Eschbach, J.W., Egrie, J.C.,
Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the
Anemia of End-Stage Renal Disease with Crecombinant Human
Erythropoietin: Results of a Combined Phase I and II Clinical Trial. New
England Journal of Medicine, 316, 73-78. http://dx.doi.org/10.1056/NEJM198701083160203 |
| [2] | Gotloib, L., Silverberg, D., Fudin, R. and Shostak, A. (2006) Iron Deficiency Is a Common Cause of Anemia in Chronic Kidney Disease and Can Often Be Corrected with Intravenous Iron. Journal of Nephrology, 19, 161. |
| [3] | AMAG Pharmaceuticals, Inc. (2009) Feraheme (Ferumoxytol) Package Insert. Lexington. |
| [4] |
Balakrishnan, V.S., Rao, M.,
Kausz, A.T., et al. (2009) Physicochemical Properties of Ferumoxytol, a
New Intravenous Iron Preparation. European Journal of Clinical
Investment, 39, 489-496. http://dx.doi.org/10.1111/j.1365-2362.2009.02130.x |
| [5] |
Iain, C.M., et al. (2014) A
Randomized Comparison of Ferumoxytol and Iron Sucrose for Treating Iron
Deficiency Anemia in Patients with CKD CJASN ePress. http://dx.doi.org/10.2215/CJN.05320513 eww141107lx |
评论
发表评论